

# Bruno Coudert

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2129041/bruno-coudert-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

524  
citations

8  
h-index

22  
g-index

22  
ext. papers

852  
ext. citations

6.1  
avg, IF

2.87  
L-index

#	Paper	IF	Citations
18	Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.. <i>European Journal of Cancer</i> , <b>2022</b> , 165, 13-24	7.5	0
17	Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267242	2.7	42
16	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 723-733	2.2	94
15	Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 359-370	7.5	9
14	Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 27, 235-237	1.7	1
13	Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , <b>2021</b> , 161, 98-107	5.9	0
12	Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018). <i>European Journal of Cancer</i> , <b>2020</b> , 141, 209-217	7.5	5
11	Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. <i>Breast</i> , <b>2020</b> , 52, 50-57	3.6	8
10	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 519-530	21.7	159
9	A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients. <i>BMC Cancer</i> , <b>2020</b> , 20, 96	4.8	6
8	Monitoring HSP70 exosomes in cancer patientsXfollow up: a clinical prospective pilot study. <i>Journal of Extracellular Vesicles</i> , <b>2020</b> , 9, 1766192	16.4	32
7	Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. <i>EClinicalMedicine</i> , <b>2020</b> , 28, 100566	11.3	1
6	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , <b>2019</b> , 30, 766-773	10.3	46
5	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 957-966	12.9	28
4	Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2019</b> , 241, 49-55	2.4	4
3	Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 24860-70	3.3	20
2	Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study. <i>Nutrition and Cancer</i> , <b>2014</b> , 66, 1092-6	2.8	8

- 1 Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 1493-1502 21.7 89